Diabetic ketoacidosis associated with orlistat treatment

被引：11

作者：

Azar, ST ^{[1
]}

Zantout, MS ^{[1
]}

机构：

[1] Amer Univ Hosp, Dept Internal Med, Div Endocrinol, New York, NY 10022 USA

来源：

DIABETES CARE | 2001年 / 24卷 / 03期

关键词：

D O I：

10.2337/diacare.24.3.602

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：602 / 602

页数：1

共 5 条

[1]

Benazzi F, 2000, CAN J PSYCHIAT, V45, P87

[2] Orlistat, a new lipase inhibitor for the management of obesity [J].

Heck, AM ;

Yanovski, JA ;

Calis, KA .

PHARMACOTHERAPY, 2000, 20 (03) :270-279

[3] Orlistat - A review of its use in the management of obesity [J].

Hvizdos, KM ;

Markham, A .

DRUGS, 1999, 58 (04) :743-760

[4] Drug points - Orlistat associated with hypertension [J].

Persson, M ;

Vitols, S ;

Yue, QY .

BRITISH MEDICAL JOURNAL, 2000, 321 (7253) :87-87

[5] THE EFFECT OF THE GASTROINTESTINAL LIPASE INHIBITOR, ORLISTAT, ON SERUM-LIPIDS AND LIPOPROTEINS IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA [J].

TONSTAD, S ;

POMETTA, D ;

ERKELENS, DW ;

OSE, L ;

MOCCETTI, T ;

SCHOUTEN, JA ;

GOLAY, A ;

REITSMA, J ;

DELBUFALO, A ;

PASOTTI, E ;

VANDERWAL, P .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 46 (05) :405-410

← 1 →